Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Phathom Pharmaceuticals (PHAT) Operating Income (2022 - 2026)

Phathom Pharmaceuticals (PHAT) has disclosed Operating Income for 5 consecutive years, with -$15.5 million as the latest value for Q1 2026.

  • For Q1 2026, Operating Income rose 80.37% year-over-year to -$15.5 million; the TTM value through Mar 2026 reached -$96.6 million, up 66.27%, while the annual FY2025 figure was -$160.0 million, 42.34% up from the prior year.
  • Operating Income hit -$15.5 million in Q1 2026 for Phathom Pharmaceuticals, down from -$5.9 million in the prior quarter.
  • Across five years, Operating Income topped out at -$5.9 million in Q4 2025 and bottomed at -$78.9 million in Q1 2025.
  • Average Operating Income over 5 years is -$46.6 million, with a median of -$45.4 million recorded in 2022.
  • Year-over-year, Operating Income crashed 143.84% in 2024 and then skyrocketed 90.02% in 2025.
  • Phathom Pharmaceuticals' Operating Income stood at -$46.6 million in 2022, then tumbled by 49.81% to -$69.9 million in 2023, then increased by 14.97% to -$59.4 million in 2024, then surged by 90.02% to -$5.9 million in 2025, then plummeted by 161.08% to -$15.5 million in 2026.
  • According to Business Quant data, Operating Income over the past three periods came in at -$15.5 million, -$5.9 million, and -$15.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.